Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries by Ndosi, Mwidimi et al.
 1 
Validation	of	the	educational	needs	assessment	tool	
as	a	generic	instrument	for	rheumatic	diseases	in	7	
European	countries		
Authors	
Mwidimi	Ndosi,1	Ann	Bremander,2	Bente	Hamnes,3	Mike	Horton,4	Marja	Leena	Kukkurainen,5	Pedro	
Machado,6	Andrea	Marques,6	Jorit	Meesters,7	Tanja	Stamm,8	Alan	Tennant,4	Jenny	de	la	Torre-
Aboki,9	Theodora	P.M.	Vliet	Vlieland,7	Heidi	A	Zangi,10	Jackie	Hill.1		
Author	affiliations	
1. Academic	&	Clinical	Unit	for	Musculoskeletal	Nursing	(ACUMeN),	Leeds	Institute	of	Rheumatic	
and	Musculoskeletal	Medicine,	University	of	Leeds,	Leeds,	UK.	
2. Research	and	Development	Center,	Spenshult	Hospital	for	Rheumatic	Diseases,	Oskarström,	
Sweden.	
3. Department	of	Patient	Education,	Hospital	for	Rheumatic	Diseases,	Lillehammer,	Norway.		
4. Department	of	Rehabilitation	Medicine,	Leeds	Institute	of	Rheumatic	and	Musculoskeletal	
Medicine,	University	of	Leeds,	Leeds,	UK.	
5. The	Finnish	Society	of	Rheumatology	Nurses,	Heinola,	Finland.	
6. Rheumatology	Department,	Coimbra	University	Hospital,	Coimbra,	Portugal.	
7. Department	of	Rheumatology	and	Department	of	Orthopaedics,	Leiden	University	Medical	
Center,	Leiden,	The	Netherlands.	
8. Department	of	Internal	Medicine	III,	Division	of	Rheumatology,	Medical	University	of	Vienna,	
Austria.	
9. Department	of	Rheumatology	Alicante's	General	and	University	Hospital,	Alicante,	Spain.	
10. Department	of	Rheumatology,	National	Resource	Center	for	Rehabilitation	in	Rheumatology	
(NRRK),	Diakonhjemmet	Hospital,	Oslo,	Norway.	
Corresponding	author’s	details	
Dr	Mwidimi	Ndosi		
Academic	&	Clinical	Unit	for	Musculoskeletal	Nursing	(ACUMeN),		
Leeds	Institute	of	Rheumatic	and	Musculoskeletal	Medicine,	University	of	Leeds,		
Postal	Address:	2nd	Floor,	Chapel	Allerton	Hospital,	Chapeltown	Road,	Leeds,	LS7	4SA,	UK.		
Tel:	+44	1133924859,	Fax:	+44	1133924991	
Email:	M.E.Ndosi@Leeds.ac.uk	
 
 2 
ABSTRACT	
Objectives	 To	 validate	 the	 educational	 needs	 assessment	 tool	 (The	 ENAT)	 as	 a	 generic	 tool	 for	
assessing	the	educational	needs	of	patients	with	rheumatic	diseases	in	European	Countries.	
Methods	A	convenience	sample	of	patients	from	seven	European	countries	was	included,	comprising	
the	 following	 diagnostic	 groups:	 ankylosing	 spondylitis	 (AS),	 psoriatic	 arthritis	 (PsA),	 systemic	
sclerosis	 (SSc),	 systemic	 lupus	 erythematosus	 (SLE),	 osteoarthritis	 (OA)	 and	 fibromyalgia	 syndrome	
(FMS).	 Translated	 versions	 of	 the	 ENAT	 were	 completed	 through	 surveys	 in	 each	 country.	 Rasch	
analysis	was	used	 to	 assess	 the	 construct	 validity	of	 the	 adapted	ENATs	 including	differential	 item	
functioning	by	culture	(cross-cultural	DIF).	Initially,	the	data	from	each	country	and	diagnostic	group	
were	fitted	to	the	Rasch	model	separately,	and	then	the	pooled	data	from	each	diagnostic	group.	
Results	 The	 sample	 comprised	 3015	 patients,	 the	 majority,	 1996	 (66.2%)	 were	 women.	 Patient	
characteristics	 (stratified	 by	 diagnostic	 group)	 were	 comparable	 across	 countries	 except	 the	
educational	 background,	 which	 was	 variable.	 In	 most	 occasions,	 the	 39-item	 ENAT	 deviated	
significantly	 from	 the	 Rasch	model	 expectations	 (item-trait	 interaction	c2	p<0.05).	 After	 correction	
for	local	dependency	(grouping	the	items	into	seven	domains	and	analysing	them	as	"testlets"),	fit	to	
the	model	was	satisfied	(item-trait	interaction	c2	p>0.18)	in	all	pooled	disease	group	datasets	except	
OA	 (c2=99.91;	p=0.002).	 The	 internal	 consistency	 in	each	group	was	high	 (Person	Separation	 Index	
above	0.90).	There	was	no	significant	DIF	by	person	characteristics.	Cross-cultural	DIF	was	found	 in	
some	 items,	 which	 required	 adjustments.	 Subsequently,	 interval-level	 scales	 were	 calibrated,	 to	
enable	transformation	of	ENAT	scores	when	required.		
Conclusions	 The	 adapted	 ENAT	 is	 a	 valid	 tool	 with	 high	 internal	 consistency,	 providing	 accurate	
estimation	of	the	educational	needs	of	people	with	rheumatic	diseases.	Cross-cultural	comparison	of	
educational	needs	is	now	possible. 
. 
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Introduction	 
Patient	 education	 should	 be	 an	 integral	 part	 of	 the	management	 of	 rheumatic	 diseases.1-4	 It	 is	 an	
interactive	 process	 between	 patients	 and	 health	 care	 professionals	 aimed	 at	 enabling	 patients	 to	
participate	actively	in	their	health	care,	strengthen	their	ability	to	manage	symptoms	and	treatment,	
improve	coping	strategies	and	increase	self-care	abilities.5-7	It	is	important	for	health	professionals	to	
assess	 patient’s	 experiential	 knowledge	 about	 arthritis,	 their	 own	 expectations,	 educational	 needs	
and	priorities	before	providing	education.	This	will	help	to	tailor	education	to	 individual	needs,	and	
promote	shared	decision-making,	which	are	important	in	helping	patients	to	manage	their	illness	and	
maintain	quality	of	life.8-10	
The	 educational	 needs	 assessment	 tool	 (ENAT)	 is	 a	 self-completed	 questionnaire,	 which	 allows	
patients	 with	 arthritis	 to	 prioritise	 their	 educational	 needs.	 If	 completed	 immediately	 before	 the	
consultation,	the	health	professional	is	able	to	provide	education	based	on	the	patient’s	immediate	
priorities.11	It	was	developed	by	people	with	arthritis	and	their	practitioners	in	the	UK,	and	comprises	
39	 items	 grouped	 into	 seven	 domains:	managing	 pain	 (six	 items),	movement	 (five	 items),	 feelings	
(four	items),	disease	process	(seven	items),	treatments	(seven	items),	self-help	measures	(six	items)	
and	support	systems	(four	 items).	 Items	are	completed	by	the	use	of	Likert	scales	ranging	from	1	 -	
’not	important	at	all’	to	5	-	’extremely	important‘.	Early	research	found	the	ENAT	to	be	acceptable	to	
patients,	easy	to	complete	and	having	good	test-retest	reliability.11	The	ENAT	was	further	validated	
using	Rasch	analysis	where	it	demonstrated	a	good	fit	to	the	Rasch	model	indicating	a	good	construct	
validity	 and	 invariance	 to	 gender,	 age,	 disease	duration	 and	educational	 background.12	 In	 order	 to	
extend	 its	 use	 to	 European	 countries	 and	 allow	multinational	 comparison	 of	 educational	 needs	 of	
people	with	rheumatoid	arthritis	(RA),	the	ENAT	was	adapted	for	use	in	six	other	European	countries;	
(Finland,	 The	 Netherlands,	 Norway,	 Portugal,	 Spain	 and	 Sweden)	 and	 was	 found	 to	 have	 cross-
cultural	 validity	 and	 invariance	 with	 some	 adjustments	 required	 for	 The	 Netherlands.13	 Since	 the	
ENAT	was	intended	to	be	a	generic	measure	across	rheumatic	diseases,	further	work	was	undertaken	
in	the	UK	to	validate	it	in	other	major	rheumatic	diseases,	that	is	ankylosing	spondylitis	(AS),	psoriatic	
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arthritis	 (PsA),	 systemic	 sclerosis	 (SSc),	 systemic	 lupus	erythematosus	 (SLE),	osteoarthritis	 (OA)	and	
fibromyalgia	syndrome	(FMS).14	The	aim	of	this	study	was	to	validate	the	ENAT	as	a	generic	tool	with	
which	 to	 assess	 the	 educational	 needs	 of	 patients	 with	 rheumatic	 diseases	 in	 seven	 European	
countries.	
Methods	 
Study design and patients 
This	 was	 a	 multicentre	 European	 collaborative	 study,	 funded	 by	 a	 research	 grant	 from	 European	
League	 Against	 Rheumatism	 (EULAR	 grant	 reference	 HPR011).	 It	 followed	 a	 cross-sectional	 survey	
design,	 requiring	 patient	 completion	 of	 the	 translated	 versions	 of	 the	 ENAT	 on	 one	 occasion	 and	
testing	its	cross-cultural	validity	using	Rasch	analysis.	The	study	was	led	from	the	University	of	Leeds	
(UK)	 and	 involved	 seven	 European	 countries;	 Austria,	 Finland,	 The	Netherlands,	Norway,	 Portugal,	
Spain	and	Sweden.	 The	methods	were	 set	out	a	priori	 in	 the	 study	protocol	 (unpublished),	 and	all	
collaborating	centres	obtained	ethical	approvals	from	their	respective	countries	before	undertaking	
the	study.	
Convenience	sampling	was	used	to	recruit	patients	from	rheumatology	outpatient	clinics,	day	units,	
in-patient	wards,	databases,	 rehabilitation	centres	and/or	 from	the	community	 in	the	collaborating	
countries.	The	inclusion	criteria	were:	(i)	positive	diagnosis	of	the	target	diseases	(AS,	PsA,	SSc,	SLE,	
OA	 or	 FMS)	 (ii)	 aged	 18	 years	 or	 above	 and	 (iii)	 willingness	 and	 ability	 to	 complete	 and	 return	 a	
questionnaire.	The	exclusion	criteria	were	(i)	inability	to	complete	the	ENAT	unaided,	(ii)	having	more	
than	one	form	of	rheumatic	disease	and	(iii)	having	mental	impairment.		
Measures	
The	cross-cultural	adaptation	of	the	original	 (English)	ENAT	 into	the	respective	European	 languages	
was	previously	undertaken	in	RA,13	using	an	established	process	for	cross-cultural	adaptation	of	self-
report	measures.15	 The	 process	 involved	 five	 steps:	 (1)	 forward	 translation	 -	 from	 English	 into	 the	
target	language,	(2)	synthesis	of	the	translations;	(3)	back	(blind)	translation	into	the	original	(English)	
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language;	(4)	expert	committee	review	which	decided	on	equivalence	between	the	source	and	target	
versions;	and	(5)	test	of	the	pre-final	version	-	testing	the	"adapted"	version	with	30	patients.	Due	to	
inclusion	of	different	diagnostic	groups	in	the	present	study,	it	was	agreed	in	the	set-up	meeting,	to	
use	the	term	‘rheumatic	disease’	for	inflammatory	arthritis	and	connective	tissue	disease	groups,	and	
keep	‘arthritis’	for	people	with	OA.	However,	in	other	countries	such	as	Portugal	and	Spain,	the	term	
"rheumatic	disease"	was	used	 for	all	diseases,	 including	OA.	This	 is	because	 in	 those	countries	 the	
term	"arthritis"	 implies	 the	presence	on	synovitis/effusion;	and	OA	 is	also	a	 rheumatic	disease	and	
recognised	by	patients	 and	health	 care	 professionals	 as	 such	 (albeit	 degenerative	 rather	 than	inflammatory).		
The	translated	versions	of	the	ENAT	were	given	to	patients	in	their	respective	countries	to	complete	
as	 postal	 surveys	 or	 before	 their	 clinic	 consultations	 or	 at	 the	 beginning	 of	 their	 rehabilitation	
programme.	 The	 ENATs	 were	 anonymous	 but	 contained	 patients’	 demographical	 data	 such	 as	
gender,	age,	educational	background	and	self-reported	disease	duration.	Once	completed,	the	ENATs	
were	sent	by	post	 to	 the	University	of	Leeds	 for	analysis.	The	ENAT	data	were	then	entered	 into	a	
database	 (IBM	 SPSS,	 version	 19)16	 and	 were	 subjected	 into	 Rasch	 analysis	 using	 RUMM202017	
software.	
Data analysis  
Rasch	 analysis	 is	 a	 mathematical	 modelling	 technique	 used	 to	 assess	 properties	 of	 outcome	
measures	against	a	measurement	model	developed	by	the	Danish	mathematician	Georg	Rasch.18	The	
Rasch	model	provides	a	formal	representation	of	 fundamental	measurement,	and	 in	Rasch	analysis	
the	observed	data	 from	questionnaires	 are	measured	 against	 the	Rasch	model	 to	 assess	 how	well	
they	 ’fit‘	 the	 model.	 Fit	 to	 the	 model	 implies	 a	 criterion-related	 construct	 validity,	 reliability	 and	
statistical	sufficiency.19-21	Further	details	of	Rasch	Analysis	tests	of	fit	are	published	elsewhere.22	
All	 ENAT	 items	 were	 assessed	 individually	 and	 collectively	 for	 fit	 to	 the	 model,	 testing	 for	 the	
assumption	of	local	independence	of	items	and	the	overall	fit.	Local	independence	means	that	items	
that	fit	the	Rasch	model	are	expected	to	be	independent	of	each	other,	that	is,	there	should	not	be	
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any	correlation	between	two	items	after	the	effect	of	the	underlying	construct	is	conditioned	out.23	
In	 the	analysis,	 the	 items	 that	were	 found	 to	be	 locally	dependent	 (a	correlation	of	±0.3	being	 the	
threshold	 for	 local	dependency)24	were	combined	 into	a	subtest	and	treated	as	a	 ’testlet‘,	which	 is	
defined	 as	 a	 subset	 of	 items	 that	 is	 treated	 as	 a	 measurement	 unit	 in	 test	 construction,	
administration	and/or	scoring.25		
The	data	from	each	diagnostic	group	from	each	country	were	tested	for	the	overall	fit	to	the	Rasch	
model	 and	 differential	 item	 functioning	 (DIF)	 by	 gender,	 age,	 disease	 duration	 and	 educational	
background.	 DIF	 occurs	 when	 two	 groups	 of	 equal	 ability	levels	 are	 not	 equally	 able	 to	 correctly	
answer	an	item.	If	the	factor	leading	to	DIF	is	not	part	of	the	construct	being	tested,	then	the	item	is	
biased,	 that	 is,	 	 observed	 scores	 should	depend	only	on	 latent	 construct	 scores,	 and	not	on	group	
membership	or	occasion.26-29	It	is	important	to	identify	the	biased	items,	so	that	adjustments	can	be	
made,	which	may	sometimes	involve	discarding	the	item.29	To	allow	for	group	comparisons,	age	and	
disease	duration,	which	are	continuous	data,	were	converted	into	categorical	data	by	splitting	at	the	
medians.	 Educational	 background	 was	 simply	 categorised	 as:	 those	 with	 only	 compulsory	 (basic)	
education	and	those	with	further	education.	Group	comparisons	tested	the	assumption	of	invariance	
(absence	 of	 DIF)	 of	 the	 ENAT	 across	 all	 patient	 subgroups,	 that	 is	 	 age	 groups,	 gender,	 disease	
duration	 and	 educational	 background.	 Following	 country-specific	 analyses,	 the	 data	was	 pooled	 in	
each	 disease	 group	 and	 fit	 to	 the	 Rasch	 model	 was	 assessed.	 The	 pooled	 data	 were	 additionally	
tested	for	DIF	by	culture	(cross-cultural	bias).	Where	cross-cultural	DIF	was	found,	a	post-hoc	(Tukey	
test)	 was	 performed	 to	 assess	 where	 the	 significant	 difference	 lies,	 and	 the	 biased	 items	 were	
adjusted	for	the	using	the	method	described	by	Tennant	et	al29		and	Brodersen	et	al.28	
The	 overall	 fit	 statistics	 are	 reported	 as	 c2	 probability,	 where	 p-value	 is	 expected	 to	 be	 non-
significant	for	adequate	fit	to	the	model.	In	most	analyses,	the	p-values	were	Bonferroni-adjusted	to	
the	alevel	(ie,	p	=	0.05/number	of	tests	carried	out),	to	avoid	type	I	errors	due	to	multiple	testing.30	
Reliability	 is	 reported	as	Person	Separation	 Index	 (PSI),	which	estimates	 the	 internal	consistency	of	
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the	scale	equivalent	to	Cronbach's	a,	only	using	the	 logit	value	as	opposed	to	the	raw	score	 in	the	
same	formulae.	A	minimum	value	of	0.7	is	required	for	group	use	and	0.85	for	individual	use.22		
Following	 fit	 to	 the	 Rasch	model,	 the	 test	 of	 strict	 unidimensionality	 of	 the	 ENAT	was	 conducted	
using	the	t-test	method	suggested	by	Smith,31	where	unidimensionality	is	confirmed	if	less	than	5%	of	
independent	t-tests	on	the	latent	estimates	derived	from	two	independent	sets	of	items	lie	outside	
the	 ±1.96	 range.	 The	 ENATs	 were	 then	 calibrated	 into	 an	 interval-level	 scale	 to	 allow	 for	 Rasch-
transformation	of	the	ordinal	data	into	interval	level	data	when	required.32	
Results  
A	 total	 of	 3219	 patients	 were	 recruited	 in	 this	 study.	 In	 all,	 74	 patients	 with	 undifferentiated	
spondyloarthropathy	from	Sweden	and	130	with	RA	from	Austria	were	excluded	from	the	analysis,	as	
these	diagnostic	groups	were	not	included	in	the	protocol.	This	meant	that	data	from	3015	patients	
were	 analysed.	 Patient	 characteristics	 (stratified	 by	 diagnostic	 group)	 were	 comparable	 across	
countries	except	for	educational	background,	which	was	variable.	Table	1	 summarises	the	country-
specific	gender	distribution,	mean	age,	disease	duration,	educational	background	and	the	availability	
of	data	in	each	diagnostic	group.		
Table	1	Sample	characteristics	by	country	
Country	 Gender	 Age	 Disease	
duration	
Educational	
background	
Diagnostic	groups	 	
	 Female	(%)	 Mean	(SD)	 Mean	(SD)	 Only	basic	
education	(%)	
AS	 PsA	 SSc	 SLE	 OA	 FMS	 Sample	
size	(N)	
Austria	 96	(55.8)	 55.3	(11.1)	 12.5	(10.6)	 86	(51.5)	 -	 125	 -	 -	 47	 -	 172	
Finland	 368	(82.1)	 53.2	(12.1)	 12.2	(10.3)	 115	(24.6)	 84	 86	 171	 -	 -	 108	 449	
The	
Netherlands	
368	(69.0)	 53.3	(15.1)	 13.8	(11.9)	 37	(6.7)	 85	 112	 103	 126	 126	 -	 552	
Norway	 398	(68.9)	 51.9	(12.0)	 10.6	(9.9)	 143	(24.4)	 146	 147	 -	 -	 149	 144	 586	
Portugal	 362	(64.0)	 50.8	(15.3)	 13.0	(10.1)	 228	(42.1)	 121	 132	 28	 146	 88	 53	 568	
Spain	 321	(63.8)	 48.2	(13.8)	 12.6	(9.8)	 180	(37.0)	 141	 124	 59	 99	 23	 57	 503	
Sweden	 83	(44.9)	 55.8	(12.5)	 21.0	(12.1)	 55	(29.7)	 102	 83	 -	 -	 -	 -	 185	
Pooled	 1996	(66.2)	 52.6	(13.1)	 13.7	(10.7)	 844.0	(28.0%)	 679	 809	 361	 371	 433	 362	 3015	
AS,Ankylosing	spondylitis;	FMS,	fibromyalgia	syndrome;	OA,	Osteoarthritis;	PsA,	Psoriatic	arthritis;	SLE,	Systemic	lupus	erythematosus;	SSc,	
Systemic	sclerosis.	 
The	data	from	each	diagnostic	group	and	country	were	fitted	to	the	Rasch	model	separately	(Table	2)	
and	then	they	were	pooled	into	diagnostic	group	datasets	(Table	3).	 In	most	diagnostic	groups	(AS,	
PsA,	SSc	and	SLE),	the	five	response	categories	(Likert	scales)	were	found	to	work	as	expected.	The	
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preliminary	analysis	of	the	individual	39	items	resulted	in	significant	deviation	from	the	Rasch	model,	
that	is,		the	p	values	of	the	c2	interaction	were	significant	in	all	disease	groups	(Table	2:	Analysis	1).	
Lack	 of	 fit	 to	 the	 model	 was	 caused	 by	 significant	 correlations	 of	 items	 within	 each	 domains	 (a	
residual	 correlation	 of	 ±0.3	 being	 the	 threshold	 for	 local	 dependency).24	 Correction	 for	 local	
dependency	involved	grouping	the	39	items	into	their	respective	seven	domains	(ie,	pain,	movement,	
feelings,	disease	process,	treatments,	self-help	and	support)	and	scoring	the	ENAT	as	a	‘seven-testlet’	
scale.	Fit	to	the	Rasch	model	was	achieved	in	all	country–specific	data	following	correction	for	local	
dependency	 with	 the	 exception	 of	 the	 OA	 disease	 group	 from	 Portugal.	 In	 all	 country-specific	
datasets,	the	internal	consistency	was	high	(PSI>0.88	-	PSI	of	0.7	is	required	for	group	use)	(Table	2:	
Analysis	2).	These	results	mean	that	the	domain	(subscale)	scores	of	the	ENAT	can	be	summed	up	to	
give	a	total	score.	
Table	2	 Country-specific	results	of	Rasch	analysis	
	 	 	
Item	Fit	
Residual	
Person	Fit	
Residual	 Chi	Square	Interaction	 	 	 Proportion	of	
significant	(95%	CI)		 	 Analysis	 Mean	 SD	 Mean	 SD	 Value	(df)	 p	 PSI	 N	
Norway	 AS
	 Analysis	1	 0.315	 1.643	 -0.238	 1.186	 163.045	(78)	 0.001	 0.97	 142	 	
Analysis	2	 0.189	 0.87	 -0.322	 1.131	 12.005	(14)	 0.606	 0.947	 142	 0.085	(0.049,	0.120)	
Finland	 AS
	 Analysis	1	 0.418	 1.197	 -0.214	 2.136	 38.262	(39)	 0.503	 0.969	 85	 	
Analysis	2	 0.421	 0.612	 -0.237	 1.102	 8.780	(7)	 0.269	 0.927	 85	 0.094	(0.048,	0.140)	
Sweden	 AS
	 Analysis	1	 0.379	 0.991	 -0.25	 2.136	 121.031	(78)	 0.001	 0.901	 102	 	
Analysis	2	 0.38	 0.624	 -0.277	 1.19	 6.818	(7)	 0.448	 0.623	 102	 0.040	(-0.003,	0.082)	
The	
Netherlands	 A
S	 Analysis	1	 0.355	 1.362	 -0.261	 2.208	 50.328	(39)	 0.106	 0.978	 82	 	
Analysis	2	 0.481	 0.998	 -0.25	 1.167	 4.281	(7)	 0.747	 0.947	 82	 0.123	(0.076,	0.171)	
Portugal	 AS
	 Analysis	1	 0.421	 1.353	 -0.662	 2.946	 54.546	(39)	 0.502	 0.966	 121	 	
Analysis	2	 0.372	 0.291	 -0.364	 1.205	 6.021	(7)	 0.537	 0.902	 121	 0.057	(0.019,	0.097)	
Spain	 AS
	 Analysis	1	 0.277	 1.947	 -0.289	 2.199	 184.606	(78)	 0.001	 0.976	 129	 	
Analysis	2	 0.301	 1.116	 -0.345	 1.175	 12.970	(14)	 0.529	 0.953	 128	 0.070	(0.033,	0.108)	
Austria		 Ps
A	 Analysis	1	 0.286	 1.147	 -0.382	 2.041	 97.313	(78)	 0.068	 0.967	 123	 	
Analysis	2	 0.611	 1.021	 -0.363	 1.284	 11.541	(14)	 0.643	 0.931	 119	 0.076	(0.036,	0.115)	
Norway	 Ps
A	 Analysis	1	 0.379	 1.258	 -0.08	 1.671	 156.851	(78)	 <0.001	 0.969	 142	 	
Analysis	2	 0.442	 0.654	 -0.237	 1.023	 10.012	(14)	 0.761	 0.933	 142	 0.056	(0.021,	0.093)	
Finland	 Ps
A	 Analysis	1	 0.297	 1.121	 -0.159	 2.032	 55.614	(39)		 0.041	 0.977	 82	 	
Analysis	2	 0.138	 0.88	 -0.256	 1.041	 6.044	(7)	 0.535	 0.954	 82	 0.061	(0.014,	0.108)	
Sweden	 Ps
A	 Analysis	1	 0.432	 1.003	 -0.269	 2.169	 51.271	(39)	 0.09	 0.96	 82	 	
Analysis	2	 0.519	 0.617	 -0.39	 1.281	 10.698	(7)	 0.152	 0.91	 82	 0.074	(0.027,	0.122)	
The	 Ps
A	 Analysis	1	 0.609	 1.708	 -0.233	 2.301	 77.078	(39)	 <0.001	 0.974	 110	 	
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Netherlands	 Analysis	2	 0.805	 1.316	 -0.255	 1.181	 6.117	(7)	 0.526	 0.936	 108	 0.093	(0.051,	0.134)	
Portugal	 Ps
A	 Analysis	1	 0.379	 1.862	 -0.679	 2.986	 162.025	(78)	 <0.001	 0.983	 126	 	
Analysis	2	 0.438	 1.119	 -0.499	 1.357	 12.743	(14)		 0.547	 0.959	 126	 0.065	(0.026,	0.103)	
Spain	 Ps
A	 Analysis	1	 0.544	 1.761	 -0.169	 2.166	 90.500	(39)	 <0.001	 0.974	 115	 	
Analysis	2	 0.44	 1.154	 -0.301	 1.125	 5.473	(7)	 0.602	 0.954	 114	 0.070	(0.030,	0110)	
Finland	 SS
c	 Analysis	1	 0.532	 1.596	 -0.476	 2.613	 126.607	(78)	 <0.001	 0.969	 167	 	
Analysis	2	 0.297	 0.897	 -0.427	 1.32	 17.624	(14)	 0.224	 0.929	 167	 0.083	(0.051,	0.117)	
The	
Netherlands	 S
Sc
	 Analysis	1	 0.453	 1.59	 -0.188	 2.154	 89.627	(39)	 <0.001	 0.978	 99	 	
Analysis	2	 0.836	 0.745	 -0.248	 1.248	 6.862	(7)	 0.443	 0.951	 99	 0.040	(-0.003,	0.083)	
Portugal	 SS
c	 Analysis	1	 0.38	 0.798	 0.055	 1.999	 22.310	(39)	 0.985	 0.977	 28	 	
Analysis	2	 0.645	 0.529	 -0.011	 0.975	 3.037	(7)	 0.882	 0.938	 28	 0.107	(0.026,	0.188)	
Spain	 SS
c	 Analysis	1	 0.291	 1.146	 -0.052	 1.748	 52.626	(39)	 0.071	 0.98	 39	 	
Analysis	2	 0.475	 0.859	 -0.057	 0.881	 4.891	(7)	 0.673	 0.969	 39	 0.051	(-0.017,	0.120)	
The	
Netherlands	 S
LE
	 Analysis	1	 0.511	 1.818	 -0.329	 2.626	 112.920	(39)	 <0.001	 0.970	 123	 	
Analysis	2	 0.397	 1.176	 -0.346	 1.244	 5.862	(7)	 0.556	 0.939	 123	 0.059	(0.020,	0.098)	
Portugal	 SL
E	 Analysis	1	 0.182	 1.264	 -0.426	 2.405	 164.349	(78)	 <0.001	 0.973	 142	 	
Analysis	2	 0.416	 0.957	 -0.423	 1.317	 11.591	(14)	 0.639	 0.936	 142	 0.049	(0.013,	0.085)	
Spain	 SL
E	 Analysis	1	 0.508	 1.542	 -0.020	 1.700	 104.037	(39)	 <0.001	 0.964	 95	 	
Analysis	2	 0.494	 0.651	 -0.233	 1.053	 19.581	 0.144	 0.933	 95	 0.055	(0.010,	0.100)	
Finland	 FM
S	 Analysis	1	 0.262	 1.401	 -0.192	 1.824	 57.954	(39)	 0.026	 0.969	 105	 	
Analysis	2	 0.324	 0.879	 -0.171	 0.953	 3.438	(7)	 0.842	 0.936	 105	 0.059	(0.017,	0.101)	
Norway	 FM
S	 Analysis	1	 0.267	 1.612	 -0.107	 1.529	 126.819	(78)	 <0.001	 0.96	 133	 	
Analysis	2	 0.222	 0.736	 -0.257	 1.009	 12.144	(14)	 0.595	 0.928	 133	 0.045	(0.008,	0.082)	
Portugal	 FM
S	 Analysis	1	 0.527	 0.725	 -0.227	 2.635	 73.211	(39)	 <0.001	 0.99	 41	 	
Analysis	2	 0.687	 0.589	 -0.128	 1.201	 7.339	(7)	 0.394	 0.984	 41	 0.073	(0.006,	0.140)	
Spain	 FM
S	 Analysis	1	 0.388	 1.518	 0.166	 1.548	 120.972	(39)	 <0.001	 0.971	 50	 	
Analysis	2	 0.195	 0.640	 -0.105	 0.706	 8.157	(7)	 0.319	 0.946	 50	 0.040	(-0.020,	0.100)	
Austria	OA	 O
A	 Analysis	1	 0.147	 0.827	 -0.122	 1.794	 61.360	(39)	 0.013	 0.951	 47	 	
Analysis	2	 0.55	 1.136	 -0.224	 1.141	 12.759	(7)	 0.078	 0.886	 47	 0.085	(0.023,	0147)	
The	
Netherlands		 O
A	 Analysis	1	 0.431	 1.497	 -0.257	 2.42	 333.770	(273)	 0.007	 0.976	 121	 	
Analysis	2	 0.294	 0.784	 -0.284	 1.154	 5.692	(7)	 0.576	 0.947	 121	 0.041	(0.003,	0.081)	
Norway	 O
A	 Analysis	1	 0.227	 1.489	 -0.255	 1.72	 113.076	(78)	 0.006	 0.97	 138	 	
Analysis	2	 0.395	 0.811	 -0.296	 1.103	 16.310	(14)	 0.295	 0.947	 138	 0.044	(0.007,	0.081)	
Portugal		 O
A	
Analysis	1	 -0.427	 1.832	 -1.885	 3.593	 78.487	(39)	 <0.001	 0.992	 77	 	
Analysis	2	 0.493		 1.710		 -0.452		 1.350		 14.765	(7)		 0.039		 0.987		 77	 0.064	(0.016,	0.114)	
Spain	 O
A	 Analysis	1	 0.284	 0.8	 0.143	 2.329	 70.762	 0.001	 0.95	 23	 	
Analysis	2	 0.272	 0.543	 -0.121	 0.967	 7.426	(7)	 0.386	 0.89	 23	 0.130	(0.041,	0.220)	
Expected	values	for	a	perfect	
model	fit	 0	 1	 0	 1	 	 >	0.05	 >	0.70	 	
Lower-bound	CI	
<0.05	
Analysis	1=Rasch	analysis	of	the	ENAT	as	a	39-item	scale;	Analysis	2=Rasch	analysis	of	the	ENAT	as	a	7-domain	scale.	AS,Ankylosing	
spondylitis;	DF,	degrees	of	freedom,	ENAT,	educational	needs	assessment	tool;	FMS,	fibromyalgia	syndrome;	OA,	Osteoarthritis;	P,	c2	
probability,	(significant	p,	item	misfit);	PsA,	Psoriatic	arthritis;	PSI,	Person	Separation	Index;	SLE,	Systemic	lupus	erythematosus;	SSc,	
Systemic	sclerosis.	
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In	each	pooled	(diagnostic-specific)	data,	fit	to	Rasch	model	was	also	satisfied,	with	the	exception	of	
the	OA	dataset	(Table	3).	In	all	pooled	analyses,	person	separation	index	(PSI)	was	greater	than	0.93	
indicating	 an	 excellent	 reliability	 (internal	 consistency)	 for	 both	 group	 and	 individual	 uses.	 Strict	
unidimensionality	of	the	overall	scale	was	confirmed	in	all	disease	groups	except	 in	the	AS	and	PsA	
diagnostic	 groups	 in	which	 the	proportions	 of	 significant	 t-tests	 (95%CI)	were	 0.074	 (0.058,	 0.092)	
and	 0.071	 (0.056,	 0.086)	 respectively,	 indicating	 a	 small	 degree	 of	 multidimensionality.	 Post-hoc	
analyses	that	followed	later	(Table	4),	suggested	this	to	be	caused	by	cross-cultural	DIF.	
Table	3	 Diagnostic	group	(pooled	datasets)	results	of	Rasch	analysis	
	Diagno
stic	
group	 		
Item	Fit	
Residual	
Person	Fit	
Residual	 Chi	Square	Interaction	
PSI	
		 	Proportion	of	
significant	T-Tests	
(95%	CI)			 Analysis	 Mean	 SD	 Mean	 SD	 Value	(df)	 p	 N	
Pooled	
AS	
Analysis	1	 0.563	 2.959	 -0.557	 2.584	 683.931	(351)	 <0.001	 0.972	 661	 		
Analysis	2	 0.314	 0.905	 -0.493	 1.347	 72.674	(63)	 0.189	 0.938	 660	
0.074	(0.058,	
0.092)	
Pooled	
PsA	
Analysis	1	 0.957	 3.096	 -0.499	 2.517	 787.691	(351)	 <0.001	 0.975	 780	 		
Analysis	2	 0.575	 1.218	 -0.445	 1.279	 70.460	(63)	 0.242	 0.944	 777	
0.071	(0.056,	
0.086)	
Pooled	
SSc	
Analysis	1	 0.699	 2.232	 -0.532	 2.634	 527.415	(351)	 <0.001	 0.976	 333	 		
Analysis	2	 0.664	 1.270	 -0.384	 1.262	 43.006	(35)	 0.166	 0.949	 333	
0.051	(0.026,	
0.074)	
Pooled	
SLE	
Analysis	1	 0.560	 2.559	 -0.497	 2.551	 476.407	(234)	 <0.001	 0.969	 360	 		
Analysis	2	 0.514	 1.166	 -0.421	 1.298	 39.817	(42)	 0.567	 0.932	 358	
0.051	(0.028,	
0.074)	
Pooled	
FMS	
Analysis	1	 0.607	 2.482	 -0.251	 1.972	 450.441	(273)	 <0.001	 0.972	 329	 		
Analysis	2	 0.378	 0.986	 -0.257	 1.016	 47.060	(42)	 0.273	 0.950	 329	
0.025	(0.001,	
0.048)	
Pooled	
OA	
Analysis	1	 0.775	 2.689	 -0.701	 3.022	 709.905	(351)	 <0.001	 0.976	 430	 	
Analysis	2	 0.406	 1.845	 -0.434	 1.273	 99.906	(63)	 0.002	 0.950	 429	 Misfit	
Expected	values	for	a	
perfect	model	fit	 0	 1	 0	 1	 	 >	0.05	 >	0.70	 	
Lower-bound	CI	
<0.05	
Analysis	1=Rasch	analysis	of	the	ENAT	as	a	39-item	scale;	Analysis	2=Rasch	analysis	of	the	ENAT	as	a	7-domain	scale.	
AS,Ankylosing	spondylitis;	DF,	degrees	of	freedom,	ENAT,	educational	needs	assessment	tool;	FMS,	fibromyalgia	syndrome;	
OA,	Osteoarthritis;	P,	c2	probability,	(significant	p,	item	misfit);	PsA,	Psoriatic	arthritis;	PSI,	Person	Separation	Index;	SLE,	
Systemic	lupus	erythematosus;	SSc,	Systemic	sclerosis	
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A	 formal	 assessment	 of	 invariance	 (DIF	 analysis)	 was	 performed	 in	 the	 diagnostic	 groups	 that	
satisfied	the	Rasch	model	requirements	(AS,	PsA,	SSc,	SLE	and	FMS).	There	was	no	significant	DIF	by	
gender,	 age,	 disease	 duration	 or	 educational	 background	 in	 the	 country	 specific	 datasets.	 This	
suggests	that	the	ENAT	is	not	biased	by	person	characteristics.	However,	in	the	pooled	datasets,	DIF	
by	culture	was	detected	across	the	diagnostic	groups	indicating	a	cross-cultural	bias	especially	in	the	
PsA	disease	group	(Table	4).		
Table	4	 	Domains	adjusted	for	cross-cultural	DIF	
	 AS	 PsA	 SSc	 SLE	 FMS	
Pain	 X	 X	 S	 S	 S	
Movements	 S	 S	 S	 X	 S	
Feelings	 S	 S	 S	 S	 S	
Disease	process	 S	 X	 S	 S	 S	
Treatments	 S	 X	 X		 X		 S	
Self-help	 S	 X	 S	 S	 S	
Support	 X	 X	 X		 S	 S	
AS,	Ankylosing	spondylitis;	DIF,	differential	item	functioning;	FMS,	fibromyalgia	syndrome;	PsA,	Psoriatic	arthritis;	S,	cross-cultural	
invariance	satisfied;	SLE,	Systemic	lupus	erythematosus;	SSc,	Systemic	sclerosis;	X,	lack	of	cross-cultural	invariance.	
	
Adjustments	 were	 made	 in	 the	 biased	 items	 to	 account	 for	 the	 cross-cultural	 DIF.	 This	 involved	
‘splitting’	the	biased	item	into	two;	where	one	is	rendered	unique	for	the	affected	country	and	the	
other	for	the	rest	of	the	countries.	For	example	in	the	AS	disease	group	(Table	5),	there	are	two	pain	
testlets,	one	unique	for	Norway	and	the	other	for	the	rest	of	the	countries.	The	unsplit	(pure)	items	
act	as	 links	 in	the	calibration	of	the	scale	thus	discounting	the	cross-cultural	bias.28,29	Following	this	
adjustment,	the	resulting	testlets	were	found	to	adequately	fit	the	model	(Table	5).	This	means	that	
the	 ENAT	 can	 be	 used	 in	 its	 present	 form	within	 each	 country	without	 any	 need	 for	 adjustments.	
However,	 when	 data	 across	 countries	 are	 being	 pooled	 or	 compared,	 then	 adjustment	 for	 cross-
cultural	DIF	will	be	 required.	We	have	calibrated	DIF-adjusted	 interval-level	 scales	 for	 this	purpose	
(see	online	supplementary	tables	1-14).	
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Table	5	 	Fit	statistics	after	adjustment	for	cross-cultural	DIF	in	the	affected	testlets	
Domain	 Testlet	 Location	 SE	 Fit	Residuals	 X
2	 P	
AS	 	 	 	 	 	 	
Pain	 Pain-Norway	 -0.15	 0.03	 -1.13	 7.76	 0.56	
Pain-	Others	 -0.01	 0.01	 0.47	 14.70	 0.10	
Movement	 Movement	 0.07	 0.01	 -0.80	 10.73	 0.29	
Feelings	 Feelings	 0.04	 0.01	 -0.18	 16.08	 0.07	
Disease	process	 Disease	process	 -0.14	 0.01	 0.21	 8.11	 0.52	
Treatments	 Treatments	 0.04	 0.01	 0.83	 7.97	 0.54	
Self-Help	 Self-Help	 -0.10	 0.01	 2.04	 5.59	 0.78	
Support	 Support	–The	Netherlands	 0.15	 0.04	 -0.96	 7.18	 0.62	
Support	-	Others	 0.09	 0.01	 0.70	 10.02	 0.35	
PsA	 	 	 	 	 	 	
Pain	 Pain	-	Austria	 -0.06	 0.03	 -1.07	 6.73	 0.46	
Pain	-	Norway	 -0.70	 0.04	 0.23	 6.54	 0.48	
Pain	–	The	Netherlands	 0.13	 0.03	 -0.09	 5.69	 0.58	
	 Pain	-	Others	 0.08	 0.02	 -0.57	 5.65	 0.58	
Movement	 Movement	 0.20	 0.01	 2.51	 8.28	 0.31	
Feelings	 Feelings	 0.16	 0.01	 2.45	 4.09	 0.77	
Disease	process	 Disease	process	-	Finland	 -0.15	 0.04	 -1.93	 4.71	 0.70	
Disease	process	-	Others	 -0.13	 0.01	 -0.11	 4.99	 0.66	
Treatments	 Treatments	-	The	Netherlands	 -0.08	 0.03	 0.77	 8.07	 0.33	
Treatments-	Sweden	 -0.05	 0.03	 1.35	 5.09	 0.65	
	 Treatments	-	Others	 0.14	 0.01	 -0.27	 7.72	 0.36	
Self-Help	 Self-Help	-	The	Netherlands	 -0.22	 0.03	 2.54	 17.90	 0.01	
Self-Help	-	Portugal	 0.16	 0.03	 0.38	 3.55	 0.83	
Self-Help	-	Others	 -0.05	 0.01	 0.37	 9.73	 0.20	
Support	 Support	-	Austria	 0.49	 0.03	 1.37	 4.74	 0.69	
Support-	Finland	 -0.40	 0.05	 -0.93	 6.53	 0.48	
Support	-	Portugal	 0.21	 0.03	 0.87	 5.68	 0.58	
	 Support	-	Others	 0.25	 0.02	 0.44	 8.69	 0.28	
SSc	 	 	 	 	 	 	
Pain	 Pain	 0.06	 0.02	 0.17	 6.93	 0.23	
Movements	 Movements	 0.12	 0.02	 -0.99	 8.34	 0.14	
Feelings	 Feelings	 0.09	 0.02	 1.79	 3.37	 0.64	
Disease	process	 Disease	process	 -0.21	 0.02	 -0.02	 10.97	 0.05	
Treatments	 Treatments-	The	Netherlands	 -0.06	 0.03	 1.96	 3.50	 0.62	
Treatments-Others	 0.03	 0.02	 0.74	 5.61	 0.35	
Self-Help	 Self-Help	 -0.16	 0.02	 0.77	 4.13	 0.53	
Support	 Support	-	The	Netherlands	 0.22	 0.04	 1.23	 3.62	 0.61	
Support	-	Others	 -0.09	 0.03	 1.28	 10.51	 0.06	
SLE	 	 	 	 	 	 	
Pain	 Pain	 0.01	 0.02	 -0.13	 5.31	 0.50	
Movement	 Movements-Spain	 0.03	 0.03	 -0.43	 4.41	 0.62	
Movements	-	Others	 0.06	 0.02	 0.05	 2.28	 0.89	
Feelings	 Feelings	 -0.04	 0.02	 2.16	 5.56	 0.47	
Disease	process	 Disease	process	 -0.18	 0.01	 -0.60	 12.62	 0.05	
Treatments	 Treatments	-	Spain	 0.18	 0.02	 0.27	 4.02	 0.67	
Treatments	-	Others	 -0.02	 0.02	 0.75	 4.23	 0.65	
Self-Help	 Self-Help	 -0.12	 0.02	 0.18	 6.20	 0.40	
Support	 Support	 0.08	 0.02	 2.05	 9.22	 0.16	
FMS	 	 	 	 	 	 	
Pain	 Pain	 -0.04	 0.02	 0.40	 5.38	 0.37	
Movements	 Movements	 -0.04	 0.02	 0.68	 3.56	 0.61	
Feelings	 Feelings	 -0.05	 0.02	 0.79	 3.20	 0.67	
Disease	process	 Disease	process	 -0.13	 0.02	 -1.24	 6.88	 0.23	
Treatments	 Treatments	 0.28	 0.02	 1.96	 5.52	 0.36	
Self-Help	 Self-Help	 -0.08	 0.02	 0.13	 8.72	 0.12	
Support	 Support	-	The	Netherlands	 0.06	 0.02	 -0.14	 6.12	 0.29	
SE	=	Standard	error,	P	=	Bonferroni-adjusted	Χ2	probability,	(non-significant	P	=	Fit	to	the	model),	
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Following	adjustment	 to	 the	 cross-cultural	DIF	 (in	 the	AS,	 PsA,	 SSc	 and	SLE	diagnostic	 groups),	 the	
raw	ENAT	domain	scores	were	mapped	against	the	corresponding	Rasch-transformed	scores	(based	
in	 logits)	 and	were	 linearly	 transformed	 to	 calibrate	 interval-level,	DIF-adjusted	 scales	of	 the	 same	
range	 (see	online	 supplementary	 tables	 1-14).	 The	details	 on	 the	use	 and	 scoring	of	 the	 ENAT	are	
given	in	the	online	supplementary	material.		
Discussion  
This	study	set	out	to	test	the	cross-cultural	validity	of	the	ENAT	as	a	generic	measure	of	educational	
needs	 in	 people	 with	 AS,	 PsA,	 SSc,	 SLE,	 OA	 and	 FMS	 in	 different	 European	 countries.	 The	 results	
indicate	 that,	 following	 its	 adaptation;	 the	 ENAT	maintained	 its	 validity	 in	 each	disease	 group	 that	
was	 tested	 (with	 limitations	 in	 OA).	 The	 implications	 of	 the	 results	 in	 terms	 of	 clinical	 use	 and	
measurement	aspects	are	set	out	below.		
In	 the	 clinical	 practice,	 the	 ENAT	 is	 used	 as	 a	 template/checklist	 to	 assess	 what	 are	 the	 most	
important	educational/informational	needs	from	the	patient’s	point	of	view.	Patients	using	the	ENAT	
have	 consistently	 found	 it	 easy	 to	 complete	 and	 effective	 in	 identifying	 their	 needs	 and	 raise	
questions	 which	 they	 would	 not	 have	 otherwise	 considered.12,33	 This	 information,	 along	 with	 the	
clinicians’	 insight	of	what	the	patient	needs	to	know,	allows	the	provision	of	timely	and	meaningful	
education	 tailored	 to	 the	 needs	 of	 each	 individual	 patient.	 When	 used	 in	 this	 way	 (for	 clinical	
purposes),	 the	 ENAT	 does	 not	 need	 scoring.	 However,	 when	 used	 as	 an	 outcome	measure	 or	 for	
comparison	of	educational	needs	across	groups,	then	the	measurement	properties	of	the	ENAT	need	
to	be	considered.	
From	the	measurement	point	of	view,	the	adapted	ENAT	has	been	shown	to	fit	the	Rasch	model,	a	
requirement	 for	questionnaires	with	 items	 that	 are	 intended	 to	be	 summed	 together	 to	provide	a	
total	 score.22	While	 the	 level	of	 ‘educational	needs’	 represented	by	each	domain	may	differ	across	
disease	groups,	 fit	 to	the	Rasch	model	confirms	the	validity	of	the	 ‘educational	needs’	construct	as	
measured	 by	 the	 ENAT	 in	 each	 disease	 group	 (with	 limitations	 in	 OA).	 Local	 dependency	was	 the	
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main	 issue	affecting	measurement	properties	of	 the	ENAT.	Since	 the	 items	within	a	domain	are	by	
definition	 related,	 it	was	 not	 surprising	 to	 find	 significant	 item-item	 correlations	within	 respective	
domains.	This	was	also	seen	in	a	similar	study	in	RA.13	Correction	for	this	may	involve	removing	the	
redundant	items	or	grouping	all	the	locally-dependent	items	into	a	testlet	(hence	scoring	them	as	a	
unit).	We	used	the	‘testlet’	approach	as	it	helps	to	retain	the	clinically	relevant	items,	yet	meeting	the	
measurement	 requirements	 of	 the	 scale.	 This	 approach	 to	 scoring	 is	 similar	 to	 that	 used	 in	 other	
scales	such	as	the	HAQ34	and	the	HADs.35	
While	 the	 ENAT	 was	 invariant	 to	 person	 characteristics,	 some	 items	 worked	 differently	 in	 some	
countries	 especially	 in	 the	OA	 and	 SpA	 disease	 groups.	 Therefore,	when	 the	 data	 across	 different	
countries	are	combined/compared,	adjustments	will	be	required	(cross-cultural	comparisons	are	not	
possible	 in	 OA).	 We	 have	 calibrated	 interval-level	 scales	 (see	 online	 supplementary	 tables	 1-14),	
which	are	adjusted	to	cross-cultural	DIF,	thus	enabling	accurate	estimation	of	educational	needs	and	
comparison	across	the	countries	when	required.	Previous	estimation	of	educational	needs	for	people	
with	 arthritis	 used	 the	 ENAT	 ordinal	 measures	 and	 non-parametric	 methods,33,36	 which	 can	 be	
limiting	 if	other	outcome	measures	have	 to	be	 taken	 into	account	 in	 the	analyses	such	as	 in	 linear	
regression	 models.	 Conversion	 of	 the	 ordinal	 measures	 into	 interval	 levels	 (Rasch-transformed	
values)	 enables	 the	 use	 of	 ENAT	 scores	 in	 parametric	 analyses,32	 alongside	 other	measures,	 given	
adequate	sample	sizes	and	normal	distribution.	Recently,	Rasch-transformed	scores	 from	the	ENAT	
have	been	used	to	assess	to	its	correlation	with	disease	activity	and	disability	in	RA	and	PsA.37		
While	 the	 ENAT	 remains	 a	 valid	 country-specific	measure	 of	 education	 needs	 for	 people	with	OA,	
strong	conclusions	cannot	be	made	about	its	cross-cultural	validity,	which	warrants	further	research.	
One	of	the	reasons	for	the	lack	of	fit	in	this	group	may	be	the	inherent	heterogeneous	nature	of	OA,	
where	educational	needs	of	patients	with	hand	OA	may	be	different	from	those	of	patients	with	hip	
or	knee	OA.	This	implies	that	when	assessing	the	educational	needs	of	people	with	OA,	the	data	from	
different	countries	should	not	be	pooled	until	their	cross-cultural	validity	has	been	established.		
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This	 study	 has	 four	main	 limitations.	 First,	 in	most	 countries	 the	 data	were	 collected	 from	 limited	
sources	and	therefore	not	representative	of	the	countries	involved.	However,	this	does	not	affect	the	
conclusions	of	this	tool	validation	research,	as	this	research	did	not	set	out	to	assess	the	educational	
needs	but	rather	to	determine	the	validity	of	the	ENAT	and	its	psychometric	properties	following	its	
adaptation.	Second,	not	all	disease	groups	were	represented	in	each	country.	Therefore	the	results	
apply	only	in	the	available	disease	groups.	Third,	being	a	cross-sectional	study,	the	ENAT’s	stability	to	
change	has	not	been	established.	However,	 given	 the	nature	of	needs	assessment,	 it	 is	difficult	 to	
establish	 ‘stability’	 as	 the	 educational	 needs	 are	 dynamic.	 Lastly,	 due	 to	 developments	 in	 the	
understanding	 of	 rheumatic	 diseases	 and	 their	 management,	 coupled	 by	 developments	 in	
information	technology,	the	ENAT	 items	do	not	cover	everything	there	 is	to	know	about	rheumatic	
diseases.	However	 the	ENAT	domains	 remain	 relevant	 in	assessing	patient	priorities	 and	 the	 items	
are	formulated	in	a	way	that	is	open	to	change.	Future	developments	will	address	this	limitation	by	
creating	item	banking	for	computerised	adaptive	assessment.	This	means	having	more	and	‘dynamic’	
items	but	delivering	few	targeted	items	according	to	need.		
The	instructions	of	how	the	ENAT	is	used	and	scored,	are	provided	in	the	online	supplementary	
material,	and	the	different	versions	of	the	ENAT	can	be	obtained	by	writing	to	the	Psychometric	
Laboratory	at	the	University	of	Leeds	
(http://www.leeds.ac.uk/medicine/rehabmed/psychometric/index1.htm)	or	the	corresponding	
author.		
Conclusion  
This	study	has	established	that	the	ENAT	is	a	valid	and	a	reliable	tool,	providing	an	accurate	measure	
of	educational	needs	for	people	with	rheumatic	diseases.	While	clinical	use	of	the	ENAT	as	a	simple	
checklist	 does	 not	 require	 scoring,	 its	 interval-level	 scale	 provides	 estimates	 that	 can	 be	 used	
alongside	other	variables	 in	parametric	analyses.	 In	addition,	a	 facility	 is	available	 for	cross-cultural	
comparisons	 when	 required.	 Further	 research	 is	 required	 in	 its	 use	 in	 electronic	 formats	 and	
development	as	a	computerised	adaptive	assessment.		
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